Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1114-1121

  Balagula, Yevgeniy ^a   Huston, Katherine Barth ^a,b   Busam, Klaus J ^a   Lacouture, Mario E ^a   Chapman, Paul B ^a   Myskowski, Patricia L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dermatologic toxicity; MEK inhibitor; Papulopustular rash; Selumetinib

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BENZOYL PEROXIDE; CEFALEXIN; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLOBETASOL; CORTICOSTEROID; DIPHENHYDRAMINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOCINOLONE; HYDROCORTISONE; METRONIDAZOLE; MINOCYCLINE; PIMECROLIMUS; PSEUDOMONIC ACID; SALICYLIC ACID; SELUMETINIB; SILVER NITRATE; TEMOZOLOMIDE; THYMOL; TRIAMCINOLONE; BENZIMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR;

ACNE; ADULT; AGED; ALOPECIA; ANGULAR CHEILITIS; ANTIBIOTIC THERAPY; BRADYCARDIA; CHEILITIS; CHOROID MELANOMA; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HAND PAIN; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; LUNG EMBOLISM; MACULOPAPULAR RASH; MALE; MEDICAL HISTORY; MELANOMA; MUCOSAL MELANOMA; MULTIPLE FOLLICULO CENTRIC ERYTHEMATOUS PAPULE; PAPULAR RASH; PAPULE; PAPULOPUSTULAR RASH; PARONYCHIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; PUSTULE; RASH; RETROSPECTIVE STUDY; REVIEW; SECONDARY INFECTION; SKIN FISSURE; SKIN MANIFESTATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TELANGIECTASIA; TOPICAL TREATMENT; TREATMENT RESPONSE; UVEA MELANOMA; XEROSIS; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN DISEASE;

AGED; BENZIMIDAZOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASE INHIBITORS; SKIN DISEASES;

EID: 80755177739     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9567-3     Document Type: Review

References (22)

1. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803-812
2. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491-500
3. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT et al (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001-1011
4. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S et al (2007) Biological characterization of ARRY-142886(AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13 (5):1576-1583
5. Huynh H, Soo KC, Chow PK, Tran E (2007) Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244(ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6 (1):138-146
6. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244(ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6 (8):2209-2219
7. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2008) The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244(ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14 (1):230-239
8. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, De Luca P, Bruzek L, Piens J et al (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23(23):5281-5293
9. Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G, Chapman P, Selaru P, Kim S, Ricart A, Wilner K (6 (2007) 3649 s (abstr. B109)) Clinical aspects of a phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer. Mol Cancer Ther.
10. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, smallmolecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244(ARRY-142886) in patients with advanced cancers. J Clin Oncol 26 (13):2139-2146
11. Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van der Graaf WT, Van Rossum MM, Van Herpen CM (2010) Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244(ARRY-142886) in patients with solid tumours. Acta Oncol 49 (1):110-113
12. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22(22):4456-4462
13. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D et al (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5):345-356
14. Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4(2):107-119
15. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M (2009) Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16(1):16-26
16. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55(4):657-670
17. Lacouture ME, Boerner SA, Lorusso PM (2006) Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 8(Suppl 1):S36-42
18. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610-621
19. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425-1433
20. Jost M, Kari C, Rodeck U (2000) The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol 10(7):505-510
21. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME (2010) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102(1):47-53
22. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61(4):614-620